Tenderwize
Wróć do wyszukiwania

Non-exclusive rebate agreement for Eltrombopag

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 34 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Eltrombopag (ATC-Code nach WHO: B02BX05)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

Demand is explicitly unknown and depends on patient numbers, prescribing behaviour, and pharmacy stocking behaviour; mi...

Participation documents must be obtained through the DTVP project room, and the notice says submission cannot be made v...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive supply of pharmaceutical products containing Eltrombopag.
  • Conclusion of rebate agreements under § 130a Abs. 8 SGB V in an open-house model.
Pokaż pełne podsumowanie

Open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Eltrombopag (ATC B02BX05) led by AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No individual negotiations or exclusivity apply, and the purchase volume is unknown and not guaranteed. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis.

Ryzyka

Demand is explicitly unknown and depends on patient numbers, prescribing behaviour, and pharmacy stocking behaviour; mi...

Participation documents must be obtained through the DTVP project room, and the notice says submission cannot be made v...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • For the offered medicinal product, the company must have its seat in Germany, another EU Member State, or another EEA state, as stated in the notice.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds is required.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive rebate agreement for Eltrombopag

Supply lot for a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V for the active substance Eltrombopag (ATC B02BX05). The scope excludes the indication acquired severe aplastic anemia unless the bidder holds valid patent rights or a patent-preserving licence. Open-house model means any eligible pharmaceutical company may join during the participation period; no exclusivity or individual negotiation applies. Place of performance is Dresden, Germany, with performance geography also stated as Saxony and Thuringia in the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Sep 2025 - Sep 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 30, 2026

Szczegóły zamówienia

Data publikacji
12 Aug 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
529414-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3